Distillate Capital Partners LLC Has $52.23 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Distillate Capital Partners LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 49.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 361,161 shares of the company's stock after selling 355,641 shares during the period. Johnson & Johnson accounts for about 2.6% of Distillate Capital Partners LLC's holdings, making the stock its 3rd largest position. Distillate Capital Partners LLC's holdings in Johnson & Johnson were worth $52,231,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson in the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $32,000. Finally, Conquis Financial LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $33,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.2 %

NYSE:JNJ traded up $0.29 during trading hours on Wednesday, reaching $153.91. 3,765,485 shares of the stock were exchanged, compared to its average volume of 7,957,624. The firm has a 50 day moving average of $159.39 and a 200 day moving average of $155.10. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market cap of $370.90 billion, a PE ratio of 23.14, a PEG ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson's dividend payout ratio is 74.59%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on JNJ shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Raymond James decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday. Bank of America dropped their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Leerink Partners reduced their target price on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $171.78.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.